成纤维细胞生长因子23与慢性肾脏病相关骨质疏松  

Fibroblast growth factor 23 in osteoporosis associated with chronic kidney disease

作　　者：秦启顺 王兴盛[2] 徐世红(综述)[2] 秦启发(审校) QIN Qishun;WANG Xingsheng;XU Shihong;QIN Qifa(Gansu University of Traditional Chinese Medicine,Lanzhou 730000,China;Gansu Provincial Hospital of Traditional Chinese Medicine,Lanzhou 730050,China;Gansu Provincial People's Hospital,Lanzhou 730000,China)

机构地区：[1]甘肃中医药大学,兰州730000 [2]甘肃省中医院 [3]甘肃省人民医院

出　　处：《肾脏病与透析肾移植杂志》2024年第6期561-566,共6页Chinese Journal of Nephrology,Dialysis & Transplantation

基　　金：甘肃省科技计划项目(23YFFA0052);甘肃省科技计划项目(22YF7FA104);甘肃省科技计划项目(创新基地和人才计划)(21JR7RA681);甘肃省中医药科研课题(GZKZ-2021-4);兰州市科技计划项目(2023-2-95);甘肃省卫生健康行业科研计划(GSWSQN2023-09)。

摘　　要：成纤维细胞生长因子23(FGF-23)在慢性肾病相关骨质疏松中的作用备受关注。研究表明,慢性肾脏病患者FGF-23水平显著升高,并通过复杂的反馈机制加速骨质疏松的进展。本文对FGF-23在慢性肾脏病相关骨质疏松中的作用机制及其临床应用潜力进行了全面综述,为慢性肾病患者的骨健康管理提供了新的视角与思路。Fibroblast growth factor 23(FGF-23)has garnered significant attention for its role in osteoporosis associated with chronic kidney disease(CKD).Studies have shown that FGF-23 levels are markedly elevated in CKD patients and accelerate the progression of osteoporosis through complex feedback mechanisms.This review provides a comprehensive analysis of the mechanisms underlying FGF-23's involvement in CKD-related osteoporosis and its potential clinical applications,offering new perspectives and insights for the management of bone health in CKD patients.

关 键 词：成纤维细胞生长因子23 慢性肾脏病 骨质疏松 

分 类 号：R692[医药卫生—泌尿科学] R580[医药卫生—外科学]